Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data
In this indirect comparison using reconstructed patient data, lorlatinib emerged as the most effective ALKi, showed the most favorable HR for PFS compared to the other ALKi, although it did not reach statistical significance versus alectinib and ensartinib. Additionally, lorlatinib showed the highest efficacy in the control of CNS progression.
Authors
- Vera Damuzzo (ORCID: https://orcid.org/0000-0002-3685-6789)
- Andrea Ossato (ORCID: https://orcid.org/0000-0001-8984-4733)
- Lorenzo Gasperoni (ORCID: https://orcid.org/0000-0001-6427-0809)
- Alessandro Inno (ORCID: https://orcid.org/0000-0001-6331-6908)
- Andrea Messori
- Luna Del Bono
Institutions
- University of Pisa (IT)
- University of Padua (IT)
- Ospedale Sacro Cuore Don Calabria (IT)
- Regional Health (US)
- Italian Society of Physiotherapy (IT)
- Ospedale Civile di Vittorio Veneto (IT)
- Azienda Ospedaliera Universitaria Pisana (IT)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-05-09
- DOI
- https://doi.org/10.3389/fonc.2025.1566816
- Citations
- 3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 4.56